Table 1.
Programmed cell death ligand-1 (PD-L1) expression in tumor cells and tumor microenvironment of metaplastic breast cancer, in some cases comparing data with other BCs.
| MBC | TNBC | Others | Significant Difference | ||
|---|---|---|---|---|---|
| Kalaw et al. [135] | (Antibody clone E1L3N) | n = 145 | n = 79 | ||
| PD-L1% in tumor ≥5% | 73% | ~18% | Yes | ||
| PD-L1% in immune cells ≥5% | 63% | 63% | No | ||
| Morgan et al. [133] | (Antibody clone SP263) | n = 27 | n = 119 | ||
| PD-L1% in tumor ≥ 1% | 29.6% | 10.1% | Yes | ||
| PD-L1% in immune cells ≥ 1% | 59.3% | 73.1% | No | ||
| Stephen et al. [137] | (Antibody clone E1L3N) | n = 12 | n = 18 | ||
| PD-L1% in immune cells ≥5% | 41.5% | 38% | No | ||
| Joneja et al. [30] | (Antibody clone SP142) | n = 72 | n = 218 | ||
| PD-L1% in tumor ≥5% | 46% | 6–9% | Yes | ||
| PD-L1% in immune cells ≥5% | 43% | ||||
| Lien et al. [138] | (Antibody clone SP142) | n = 82 | |||
| PD-L1% in tumor ≥1% | 17% | ||||
| PD-L1% in immune cells ≥1% | 47.5% | ||||
| Chao et al. [134] | (Antibody clone SP142) | n = 60 | |||
| PD-L1% in tumor ≥ 1% | 50% | ||||
| PD-L1% in immune cells ≥ 1% | 60% | ||||
| Vranic et al. [13] | (Antibody clone SP142) | n = 23 | |||
| PD-L1% in tumor ≥ 1% | 30.4% | ||||
| PD-L1% in immune cells ≥ 1% | 8.7% | ||||
| Dill et al. [136] | (Antibody clone SP142) | n = 5 | |||
| PD-L1% in tumor ≥ 1% | 40% | ||||
| PD-L1% in immune cells ≥5% | 80% |